Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cost of Revenue: 2022-2025

Historic Cost of Revenue for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $8.7 million.

  • Arcutis Biotherapeutics' Cost of Revenue rose 57.82% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.9 million, marking a year-over-year increase of 120.55%. This contributed to the annual value of $19.1 million for FY2024, which is 283.56% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Cost of Revenue of $8.7 million as of Q3 2025, which was up 15.92% from $7.5 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Cost of Revenue ranged from a high of $8.8 million in Q1 2025 and a low of $269,000 during Q3 2022.
  • Its 3-year average for Cost of Revenue is $4.5 million, with a median of $3.5 million in 2024.
  • Data for Arcutis Biotherapeutics' Cost of Revenue shows a peak YoY skyrocketed of 365.57% (in 2024) over the last 5 years.
  • Arcutis Biotherapeutics' Cost of Revenue (Quarterly) stood at $485,000 in 2022, then skyrocketed by 363.09% to $2.2 million in 2023, then soared by 207.44% to $6.9 million in 2024, then skyrocketed by 57.82% to $8.7 million in 2025.
  • Its Cost of Revenue stands at $8.7 million for Q3 2025, versus $7.5 million for Q2 2025 and $8.8 million for Q1 2025.